Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies
Andrea Negro, Paolo Martelletti
Expert Review of Neurotherapeutics (2019) Vol. 19, Iss. 8, pp. 769-776
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
Bianca Raffaelli, Rea Kalantzis, Jasper Mecklenburg, et al.
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 79
Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre
Andrea Negro, Paolo Sciattella, Daniele Rossi, et al.
The Journal of Headache and Pain (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 65
Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives
Eleonora De Matteis, Martina Guglielmetti, Raffaele Ornello, et al.
Expert Review of Neurotherapeutics (2020) Vol. 20, Iss. 6, pp. 627-641
Closed Access | Times Cited: 60
The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal
Raffaele Ornello, Cindy Tiseo, Ilaria Frattale, et al.
The Journal of Headache and Pain (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 44
Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
Raffaele Ornello, Alfonsina Casalena, Ilaria Frattale, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 41
Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
Oralee J. Varnado, Janna Manjelievskaia, Wenyu Ye, et al.
Patient Preference and Adherence (2022) Vol. Volume 16, pp. 821-839
Open Access | Times Cited: 27
Unmet Needs in Preventive Treatment of Migraine
Enrico Bentivegna, Dilara Onan, Paolo Martelletti
Neurology and Therapy (2023) Vol. 12, Iss. 2, pp. 337-342
Open Access | Times Cited: 16
Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation
Licia Grazzi, Frank Andrasik, Paul Rizzoli, et al.
Headache The Journal of Head and Face Pain (2021) Vol. 61, Iss. 6, pp. 895-905
Closed Access | Times Cited: 27
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
Michael Ament, Kathleen A. Day, Virginia L. Stauffer, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 25
Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
Hans-Christoph Diener, Kathleen A. Day, Sarah Lipsius, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials
Raffaele Ornello, Valeria Caponnetto, Susanna Ratti, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 22
Rapid referral for headache management from emergency department to headache centre: four years data
Andrea Negro, Valerio Spuntarelli, Paolo Sciattella, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Anti-migraine agents from an immunological point of view
Mushref Bakri Assas
Journal of Translational Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 20
Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective
Takao Takeshima, Fumihiko Sakai, Xinyu Wang, et al.
PharmacoEconomics (2024) Vol. 42, Iss. 7, pp. 811-822
Open Access | Times Cited: 2
A Prospective Observational Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment
Marialuisa Gandolfi, Valeria Donisi, Fabio Marchioretto, et al.
Toxins (2019) Vol. 11, Iss. 9, pp. 504-504
Open Access | Times Cited: 15
The clinical and public health implications and risks of widening the definition of chronic migraine
Martina Guglielmetti, Alberto Raggi, Raffaele Ornello, et al.
Cephalalgia (2019) Vol. 40, Iss. 4, pp. 407-410
Closed Access | Times Cited: 10
Chronic headaches and middle meningeal artery embolization
Joshua S. Catapano, Katherine Karahalios, Visish M. Srinivasan, et al.
Journal of NeuroInterventional Surgery (2021) Vol. 14, Iss. 3, pp. 301-303
Closed Access | Times Cited: 9
Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies
Izabela Domitrz, Aurelia Lipa, J Rózniecki, et al.
Neurologia i Neurochirurgia Polska (2020) Vol. 54, Iss. 4, pp. 337-343
Open Access | Times Cited: 7
L-arginine and aged garlic extract for the prevention of migraine: a study protocol for a randomised, double-blind, placebo-controlled, phase-II trial (LARGE trial)
Devahuti R. Chaliha, Mauro Vaccarezza, Emily J. Corti, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Practical Insights on the Identification and Management of Patients with Chronic Migraine
Andrew Blumenfeld, Aud Nome Dueland, Stefan Evers, et al.
Pain and Therapy (2022) Vol. 11, Iss. 2, pp. 447-457
Open Access | Times Cited: 4
Impact of a 12-week olfactory training programme in women with migraine with aura: protocol for a double-blind, randomised, placebo-controlled trial
Vanda Faria, Jana Dulheuer, Akshita Joshi, et al.
BMJ Open (2023) Vol. 13, Iss. 7, pp. e071443-e071443
Open Access | Times Cited: 2
Conversion From Chronic To Episodic Migraine In Patients Treated With Erenumab: Real-Life Data From An Italian Region
Raffaele Ornello, Alfonsina Casalena, Ilaria Frattale, et al.
Research Square (Research Square) (2020)
Open Access | Times Cited: 4
Impact of a 12-week open-label placebo treatment on headache days in episodic and chronic migraine: a study protocol for a parallel-group, multicentre, randomised controlled trial
Katharina Schmidt, Julian Kleine‐Borgmann, Dagny Holle, et al.
BMJ Open (2021) Vol. 11, Iss. 6, pp. e045969-e045969
Open Access | Times Cited: 3
L-arginine and aged garlic extract for the prevention of migraine: a study protocol for a randomised, double-blind, placebo-controlled, phase-II trial (LARGE trial)
Devahuti R. Chaliha, Mauro Vaccarezza, Emily J. Corti, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Fremanezumab in the prevention of migraine: a profile of its use
Yvette N. Lamb
Drugs & Therapy Perspectives (2019) Vol. 35, Iss. 12, pp. 592-600
Closed Access
Page 1 - Next Page

Scroll to top